TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04776655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: This is the treatment assigned to experimental arm:~All treatments will continue until disease progression, death, unacceptable toxicity, clinical decision or consent withdrawn.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: This is the treatment assigned to control arm:~All treatments will continue until disease progression, death, unacceptable toxicity, clinical decision or consent withdrawn.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: FOLFIRI regimen: This is the treatment assigned to control and to experimental arms:~All treatments will continue until disease progression, death, unacceptable toxicity, clinical decision or consent withdrawn.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: FOLFIRI regimen: This is the treatment assigned to control and to experimental arms:~All treatments will continue until disease progression, death, unacceptable toxicity, clinical decision or consent withdrawn.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: FOLFIRI regimen: This is the treatment assigned to control and to experimental arms:~All treatments will continue until disease progression, death, unacceptable toxicity, clinical decision or consent withdrawn.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: FOLFIRI regimen: This is the treatment assigned to control and to experimental arms:~All treatments will continue until disease progression, death, unacceptable toxicity, clinical decision or consent withdrawn.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium levofolinate
Description: FOLFIRI regimen: This is the treatment assigned to control and to experimental arms:~All treatments will continue until disease progression, death, unacceptable toxicity, clinical decision or consent withdrawn.
Study: NCT05530226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine
Description: Traditional Chinese medicine, oral administration, twice daily
Study: NCT04776655

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium levofolinate
Description: FOLFIRI regimen: This is the treatment assigned to control and to experimental arms:~All treatments will continue until disease progression, death, unacceptable toxicity, clinical decision or consent withdrawn.
Study: NCT05843734

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Equia forte HT
Description: Restoration of anterior class III caries lesions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Equia forte HT
Description: Restoration of anterior class III caries lesions
Study: NCT04906174

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Medical records are reviewed
Study: NCT05411159

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Opioid-Free Anesthesia (OFA)
Description: Opioid-free general anesthesia protocol:~After entering the operating room, patients were given dexamethasone (5mg i.v.), atropine (0.25mg i.v.), flurbiprofen (50mg i.v.), dexmedetomidine (0.5ug/kg i.v. in 15min), and ultrasound-guided T4-5 paravertebral nerve block (0.5% Ropivacaine 20ml).~Induction of anesthesia with lidocaine (1.5mg/kg i.v.), propofol (2-3mg/kg, i.v.), rocuronium (6-8mg i.v.).~Intraoperative anesthesia was maintained by desflurane (0.5-1MAC), continuous intravenous infusion of dexmedetomidine (0.5ug/kg/h), and lidocaine (1.5mg/kg/h).~Flurbiprofen (50 mg i.v.) given at the time of skin suture.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard general anesthesia (OA)
Description: Standard general anesthesia protocol:~After entering the operating room, patients were given dexamethasone (5mg i.v.), atropine (0.25mg i.v.), flurbiprofen (50mg i.v.).~Induction of anesthesia with lidocaine (1.5mg/kg i.v.), sufentanil (0.3-0.4ug/kg), propofol (2-3mg/kg, i.v.), rocuronium (6-8mg i.v. ).~Intraoperative anesthesia was maintained by desflurane (0.5-1MAC) and continuous intravenous infusion of remifentanil (0.1-0.2ug/kg/min).~Flurbiprofen (50 mg i.v.) given at the time of skin suture.
Study: NCT04586283

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maternal prone position
Description: Women will be asked to lie in a prone position supported by a specially designed cushion for 30 minutes.
Study: NCT06495034

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: airwave compression therapy
Description: Airwave compression therapy was given to patients after breast cancer surgery to treat the ipsilateral upper limb

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard care: health education and routine functional exercise
Description: standard care: health education and routine functional exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard care: health education and routine functional exercise
Description: standard care: health education and routine functional exercise
Study: NCT05013762

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fast intervention
Description: This intervention is based on recent body of evidence that high-speed movements during training are effective at improving arm movements in individuals with chronic stroke.Participants will be rewarded for movements performed within a short amount of time.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Active Monitoring
Description: This is an observation-only group. The training received in this group will be dose equivalent to the active group.
Study: NCT05173064

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Machine learning-based exercise training system
Description: The video-based exercise training system will have three key features:~1. Evidence-based exercise videos instructed by physical therapists~2. Real-time movement feedback and performance score~3. Exercise records.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video-based exercise training system
Description: The video-based system will only include the exercise videos as those involved in the machine learning-based system. The features of real-time movement feedback and tracking of exercise progress will not be provided.
Study: NCT05250063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM-201
Description: Administered orally once daily
Study: NCT06514495

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapy
Description: Cognitive behavioral psychotherapy with exposure

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapy
Description: Cognitive behavioral psychotherapy with exposure
Study: NCT06309134

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Families Bright Futures Program
Description: Seven weekly online group sessions with separate sessions for teens and caregivers. Sessions focus on increasing knowledge and acceptance of LGBTQ+ identities, alcohol use and dating violence social norms correction, bystander intervention, assertive communication skills, social emotional skills, family problem solving, and parenting behaviors.
Study: NCT06303869

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS) of the Motor Thalamus
Description: All participants enrolled in this group will undergo a surgical procedure to implant deep brain stimulation electrode leads. The electrodes will be connected to external stimulators and a series of experiments will be performed to identify the types of movements that the hand and arm can make and how speech abilities are affected by the stimulation. The implant will be removed after less than 30 days.
Study: NCT05159336

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS for auditory hallucinations via single arm
Description: a 20 weeks, weekly 40 minutes, 1mA, 10Hz-tACS protocol
Study: NCT06204835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RD-Cy7 fluorophore
Description: Fluorophore targeting ITGA6 that is overexpressed in HCC cells
Study: NCT00842322

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high fluid intake
Description: fluid intake of 4 litres per day

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: normal fluid intake
Description: Fluid intake of 2 litres per day
Study: NCT05606471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Pen Injector [Ozempic]
Description: Glucagon-like peptide 1 (GLP-1) receptor agonist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide Pen Injector [Ozempic]
Description: Glucagon-like peptide 1 (GLP-1) receptor agonist

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Very-low Calorie Diet
Description: Total meal replacement with a limit of 800 kilocalories per day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Very-low Calorie Diet
Description: Total meal replacement with a limit of 800 kilocalories per day
Study: NCT05066932

Intervention type: OTHER
Intervention: Additionnal blood samples
Description: Additionnal blood samples

Intervention type: OTHER
Intervention: Additionnal blood samples
Description: Additionnal blood samples
Study: NCT05711563

Intervention type: OTHER
Intervention: Observational study
Description: Observational study

Intervention type: OTHER
Intervention: Observational study
Description: Observational study

Intervention type: OTHER
Intervention: Observational study
Description: Observational study
Study: NCT05209633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granules Dendrobii
Description: 6g each, 3 times per day, total 18 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT05926700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candonilimab
Description: The patients were treated with Candonilimab + anlotinib, with Cadonilimab 10mg/kg, D1 administration; Anlotinib 12mg/ day was orally administered for 2 weeks and stopped for a week, with 21 days as a course of treatment.
Study: NCT04839731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination topical 5-fluorouracil 5% / calcipotriene 0.005% cream
Description: Apply twice per day for allotted time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination topical 5-fluorouracil 5% / calcipotriene 0.005% cream
Description: Apply twice per day for allotted time

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nourivan Base Cream
Description: Apply twice per day for allotted time
Study: NCT04987788

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motívate
Description: The Motívate app can be used in English or Spanish and involves four sequential phases. 1) The engaging phase uses videos to welcome participants. 2) Patients willing to discuss the decision to have a screening colonoscopy will answer multiple-choice questions on colorectal cancer prevention - completing the focusing phase. Optional videos will offer additional information. 3) The evoking phase consists of interactive Motivational Interviewing exercises to help participants elicit motivations to get a screening colonoscopy. 4) During the planning phase, participants will view a video that will discuss the steps needed to prepare for the colonoscopy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video link
Description: General health information video link
Study: NCT05739201

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: interscalene nerve block
Description: Patients will receive interscalene nerve block, in which the patient will be in supine position with the head turned to the contralateral side using an ultrasound scan to identify the C5 and C6 nerve roots between the scalene muscles.15 ml of 0.25% Bupivacaine will be deposited between the C5 and C6 nerve roots, within the interscalene groove using a 22 gauge-regional block needle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: anterior suprascapular nerve block
Description: Patients will receive anterior suprascapular nerve block, in which the patient will be in supine position with the head turned to the contralateral side, using an ultrasound the nerve will be traced as it diverges from the brachial plexus to lie under the omohyoid muscle in the supraclavicular fossa. 15 ml of 0.25% Bupivacaine will be deposited lateral to the suprascapular nerve, underneath the omohyoid muscle using a 22 gauge-regional block needle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peri-capsular nerve group block
Description: Patients will receive PENG block, in which the patient will be in supine position and the patient's arm will be placed in external rotation and abducted at 45 degrees, using an ultrasound the humeral head, the tendon of the subscapularis muscle and the deltoid muscle over it will be defined, 15 ml of 0.25% Bupivacaine will be placed between the deltoid muscle and subscapularis tendon using a 22 gauge-regional block needle.
Study: NCT05285293

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Rich Fibrin (PRF)
Description: Platelet rich fibrin (PRF) in treatment of intrabony defects using Modified Minimally invasive surgical technique (M-MIST)
Study: NCT06338969

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate Restriction after a Gastric Bypass
Description: All patients will undergo laparoscopic one anastomotic gastric bypass. In the postoperative period, all patients will receive normal daily amounts of protein and fat. Depending on the amount of carbohydrates that will be received after surgery, patients will randomly (no mask) be divided into three groups:~The first group: 51-75% deficit in carbohydrates Second group: 26-50% deficit in carbohydrates The third group: has a 1-25% deficit in carbohydrates.
Study: NCT05285293

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Fibrin (PRF) and Retinol
Description: Platelet rich fibrin (PRF) mixed with Retinol in treatment of intrabony defects using Modified Minimally invasive surgical technique (M-MIST)
Study: NCT06338969

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbohydrate Restriction after a Gastric Bypass
Description: All patients will undergo laparoscopic one anastomotic gastric bypass. In the postoperative period, all patients will receive normal daily amounts of protein and fat. Depending on the amount of carbohydrates that will be received after surgery, patients will randomly (no mask) be divided into three groups:~The first group: 51-75% deficit in carbohydrates Second group: 26-50% deficit in carbohydrates The third group: has a 1-25% deficit in carbohydrates.
Study: NCT06006793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-5933
Description: KRAS p.G12C inhibitor
Study: NCT05270070

Intervention type: OTHER
Intervention: Appointment booking system
Description: Patients were sent an email to book an appointment using the telephone/email versus a online booking system.

Intervention type: OTHER
Intervention: Appointment booking system
Description: Patients were sent an email to book an appointment using the telephone/email versus a online booking system.
Study: NCT05634967

Intervention type: OTHER
Intervention: Kesimpta
Description: Prospective non-interventional study. There is no treatment allocation. Patients participating in from the two independent sub-studies, namely the Kesimpta-OTIS sub-study and Kesimpta-DMSKW sub-study, of identical design, conducted in parallel, enrolling pregnant women (MS and non-MS) residing in US or Canada and pregnant women (MS only) from Germany respectively are eligible for enrolling to this study.
Study: NCT06045689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luspatercept
Description: Specified dose on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luspatercept
Description: Specified dose on specified days.
Study: NCT05845424

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guideline directed statin therapy
Description: At least moderate intensity statin, recommended by the current guideline based on the ASCVD risk
Study: NCT05341960

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food Delivery
Description: Food box with food to feed a family of four, delivered by the Greater Cleveland Food Bank every two weeks. Based on participant preferences, includes recipes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Financial Support
Description: Provides supplemental funds to purchase healthy foods; provides choice. Includes recipes for limited budgets and assistance locating healthy food options in their specific neighborhood.
Study: NCT05680688

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: * Postero-anterior mobilizations: the physiotherapist will place his thumbs on the posterior surface of the spinous process of the vertebra previously assessed as the most painful to mobilise. The oscillations will be performed at the frequency of 1 oscillation per second and will be performed 3 series of 3 minutes, with a 1 minute rest interval.~* Pressure: The point of greatest pain shall be treated by maintained pressure in each of the following areas: right upper trapezius, left upper trapezius, right paravertebral musculature and left paravertebral musculature. Pressure shall be applied to each of the points for 1 minute.~* Massage: Pressure is applied to the muscles by sliding along the muscle belly. This will be done slowly to control the pain that is being provoked. 3 minutes will be carried out on each upper trapezius, sliding from the acromion to the occipital and another 3 minutes on the paravertebral musculature on each side, sliding from T1 to the occipital.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy
Description: * Postero-anterior mobilizations: the physiotherapist will place his thumbs on the posterior surface of the spinous process of the vertebra previously assessed as the most painful to mobilise. The oscillations will be performed at the frequency of 1 oscillation per second and will be performed 3 series of 3 minutes, with a 1 minute rest interval.~* Pressure: The point of greatest pain shall be treated by maintained pressure in each of the following areas: right upper trapezius, left upper trapezius, right paravertebral musculature and left paravertebral musculature. Pressure shall be applied to each of the points for 1 minute.~* Massage: Pressure is applied to the muscles by sliding along the muscle belly. This will be done slowly to control the pain that is being provoked. 3 minutes will be carried out on each upper trapezius, sliding from the acromion to the occipital and another 3 minutes on the paravertebral musculature on each side, sliding from T1 to the occipital.
Study: NCT05838482

Intervention type: DEVICE
Intervention: CT Photon-Counting
Description: Enrolled subjects will complete an exam using the photon-counting CT, with or without IV contract as indicated. Images will then be compared with the previously acquired CT conducted as standard of care.
Study: NCT06424314

Intervention type: DIAGNOSTIC_TEST
Intervention: Monitoring of respiratory mechanics parameters
Description: Physiologic recording instrumentation measure maximal transdiaphragmatic pressure，twitch diaphragmatic pressure and maximal diaphragmatic electromyography

Intervention type: DIAGNOSTIC_TEST
Intervention: Monitoring of respiratory mechanics parameters
Description: Physiologic recording instrumentation measure maximal transdiaphragmatic pressure，twitch diaphragmatic pressure and maximal diaphragmatic electromyography
Study: NCT06364111

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrabot capsule
Description: Subjects in Trial Group 1 received polyethylene glycol combined with Vibrabot capsules for 2 weeks and then Vibrabot capsules for 4 weeks; Subjects in Trial Group 2 received Vibrabot capsules for 12 consecutive weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrabot capsule
Description: Subjects in Trial Group 1 received polyethylene glycol combined with Vibrabot capsules for 2 weeks and then Vibrabot capsules for 4 weeks; Subjects in Trial Group 2 received Vibrabot capsules for 12 consecutive weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: polyethylene glycol
Description: Subjects in the control group received polyethylene glycol for 6 weeks
Study: NCT04812132

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: One-anastomosis gastric bypass
Description: One group is planned to have one-anastomosis gastric bypass (also known as mini-bypass)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: One-anastomosis gastric bypass
Description: One group is planned to have one-anastomosis gastric bypass (also known as mini-bypass)
Study: NCT05768607

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Quality of Life QUESTIONNAIRE (SF36)
Description: Units of a scale of the patients will be compared pre and postoperatively by using SF36

Intervention type: PROCEDURE
Group type: OTHER
Intervention: INCONTINENCE IMPACT QUESTIONNAIRE (IIQ-7)
Description: Units of a scale of the patients will be compared pre and postoperatively by using IIQ-7

Intervention type: PROCEDURE
Group type: OTHER
Intervention: UROGENITAL DISTRESS INVENTORY (UDI - 6)
Description: Units of a scale of the patients will be compared pre and postoperatively by using UDI - 6
Study: NCT04812132

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Long biliary limb Roux gastric bypass
Description: Other group is planned to receive a long biliary limb Roux gastric bypass

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Long biliary limb Roux gastric bypass
Description: Other group is planned to receive a long biliary limb Roux gastric bypass
Study: NCT05478109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]XZP-3287
Description: 360 mg suspension containing 50µCi of \[14C\] XZP-3287
Study: NCT05798312

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Customizable support material
Description: Customizable support material will enable patients to identify their personal breast cancer information.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Non-customizable support material
Description: Non-customizable support material will include general breast cancer information.
Study: NCT00879853

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Therapy
Study: NCT05285007

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobilization with Movement
Description: Participants will be lunging on a box with posterior ankle glide of 10 seconds times 5 sets. They will have 30 seconds rest between trials. Participant will have their ankle taped and then walk on a treadmill at a self-selected pace for 5 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No mobilization with movement and education
Description: Participants ankle will not be taped and they will walk on the treadmill for 5 minutes and receive education.
Study: NCT05743959

Intervention type: PROCEDURE
Intervention: No intervention
Description: No intervention